|
You see, UCB concerns itself primarily with pharmaceuticals. The company has exited the chemicals business and is focusing on its biopharmaceutical offerings, which include both prescription drugs and other medicines in the areas of neurology, inflammation, and oncology. Its top selling drugs include Keppra (anti-seizure), Xyzal (anti-allergy), Tussionex (cough suppressant), Nootropil (cerebral function regulator), Metadate CD/Equasym XL (Attention Deficit Hyperactivity Disorder treatment), and Atarax (tranquillizer). UCB has operations in over 40 countries. The company markets products through an internal sales force and through strategic relationships with other pharma companies.
|
| | | Contact Information | |
Address: |
Allée de la Recherche 60
1070 Brussels, Belgium
| | Phone: | +32-2-559-99-99 | | Fax: | +32-2-559-99-00 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 5075.60 M | | Revenue Growth (1 yr): | (-4.90%) | | Employees (2008): | 11,292 | | Employee Growth (1 yr): | (-6.70%) |
|
|
Key People
| | • |
Chairman:
Baron Karel Boone
| | • |
Chairman, Executive Committee, and CEO:
Roch F. Doliveux
| | • |
EVP Global Operations:
William (Bill) Robinson
|
|
|
